Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Consensus Price Target of $108.11 According to Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned an average recommendation of “Hold” from the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $108.11.

LNTH has been the topic of several analyst reports. Citizens Jmp reaffirmed a “market outperform” rating and issued a $115.00 price target on shares of Lantheus in a report on Monday, June 29th. William Blair set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. TD Cowen cut Lantheus from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. Finally, Mizuho reduced their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 29th.

Lantheus Stock Up 0.2%

NASDAQ:LNTH opened at $100.18 on Thursday. Lantheus has a fifty-two week low of $49.67 and a fifty-two week high of $111.86. The stock has a market capitalization of $6.54 billion, a P/E ratio of 24.20 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The company’s 50-day simple moving average is $100.50 and its 200-day simple moving average is $96.68.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The firm had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.57 EPS. On average, equities analysts anticipate that Lantheus will post 4.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently modified their holdings of LNTH. Jupiter Topco LLC acquired a new stake in shares of Lantheus during the second quarter worth about $575,628,000. Norges Bank acquired a new position in Lantheus in the 4th quarter worth approximately $76,197,000. Assenagon Asset Management S.A. increased its holdings in Lantheus by 440.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after buying an additional 582,661 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its position in Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after buying an additional 522,678 shares during the last quarter. Finally, Summit Street Capital Management LLC purchased a new position in Lantheus during the 2nd quarter worth approximately $44,454,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.